Industry News: Randox Pioneers Health Testing Innovations at World’s Largest Diagnostics Conference

01 Aug 2018


Randox Laboratories, a leading medical diagnostics manufacturer, has showcased advancements in biotechnology at the world’s largest diagnostics conference, being held in Chicago, Illinois. The American Association of Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, known as the leading event for laboratory medicine worldwide, offers Randox the opportunity to showcase its capabilities to more than 20,000 healthcare professionals and decision makers from around the globe. Randox can be found at booth #3624.

“Our pioneering diagnostic technologies are leading the way in innovation and have real potential to transform healthcare around the world,” said Randox Managing Director, Dr. Peter FitzGerald. “At AACC we will be hosting demonstrations of a wide range of our intuitive multiplex analyzers, including the revolutionary Randox Evidence Evolution, the world’s first fully automated random-access testing platform, capable of delivering 2640 results in one hour, with the first delivered in just 37 minutes.”

The unique and unrivalled capabilities of the Randox Evidence Evolution are made possible thanks to Randox’s patented Biochip Array Technology, which can currently run 49 different tests simultaneously – ensuring an accurate and reliable diagnosis as fast as possible.

Launching at this year’s AACC event are a number of exciting new tests on the Randox Biochip, the result of a £280 million investment in research and development. Including but not exclusive to a diagnostic test for the differentiation of hemorrhagic and ischemic strokes, an algorithm capable of generating a patient’s Type 1 Diabetes Genetic Risk Score, and a test to diagnose Acute Kidney Injury (AKI) in the participants of pharmaceutical drug trials, these new tests all share the common goal of much earlier and effective diagnosis, to greatly improve healthcare outcomes and reduce the burden on healthcare services. 

Dr. FitzGerald continued; “We remain committed to developing new health diagnostic technologies for a range of the world’s most pressing health issues in need of the most urgent address, and to expanding the business in our key markets, such as the US.

“Our very significant investment in research and development means that we have more new tests in development than any other healthcare company in the world and are able each year to bring a wealth of exciting new technologies to the American market. 

“We look forward to showcasing our latest innovations at this year’s AACC conference, and how they can be utilized to save, improve and extend lives through the earliest possible diagnosis. Randox technology can truly revolutionize the future of healthcare.”

For more news from AACC, visit our Special Feature or follow at #AACC2018 on Twitter